Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)
Status:
Completed
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Since strategies were applied in intensive care medicine, including low tidal volume
ventilation, fluid resuscitation, use of antibiotics, restrictive transfusion strategy and
bundle of ventilator therapy, the incidence of Acute Respiratory Distress Syndrome (ARDS) has
been decreased recent years. However, the mortality of severe ARDS is still higher to 45%.
Few medications did were indicated to be effective in working on development of ARDS.
Different with other disease, ARDS were difficult to prevent in its later stage like a domino
effect. The medication interventions are all used after ARDS was developed, including
ulinastatin. The investigators hypothesized that the key point in failure of medication
therapy is the delay timing of medication intervention. If given the preventive strategy,
such as ulinastatin, the incidence or the severity of ARDS might be decreased. Therefore this
is a randomized controlled trial to test the hypothesis of the preventive effect of
ulinastatin in ARDS.
This is a multi-center, randomized, double blinded, placebo controlled study.
Phase:
N/A
Details
Lead Sponsor:
Peking University Third Hospital
Collaborators:
Beijing Anzhen Hospital Beijing Shijitan Hospital Affiliated to Capital Medical University Central Hospital of Zi Bo Chinese PLA General Hospital First Affiliated Hospital of Guangxi Medical University Peking University Shenzhen Hospital The First Affiliated Hospital of Zhengzhou University The Second Affiliated Hospital of Dalian Medical University